Cellumed Co.,Ltd. (KOSDAQ: 049180)

Market Cap	173.52B
Revenue (ttm)	111.87B
Net Income (ttm)	-30.25B
Shares Out	49.23M
EPS (ttm)	-676.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,153,942
Open	2,770.00
Previous Close	2,840.00
Day's Range	2,700.00 - 3,550.00
52-Week Range	1,351.00 - 4,185.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Cellumed Co.,Ltd.

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFβ-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone ...

• Industry: Business Services, not elsewhere classified
• Founded: 1985
• Employees: 99
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049180

Financial Performance

In 2023, Cellumed Co.,Ltd.'s revenue was 95.55 billion, a decrease of -21.73% compared to the previous year's 122.09 billion. Losses were -37.30 billion, 569.5% more than in 2022.